ILCSC goes virtual

LUNGevity is excited to announce that the International Lung Cancer Survivorship Conference, now in its 10th year, will be virtual this year. The virtual format allows us to offer even more great expert speakers, sessions, and meetups.

Best of all, this transformative event will now be available to more people affected by lung cancer. We will be able to offer this conference that has positively educated, supported, and provided community to so many to a larger audience through the virtual format.

The event will be streamed to you in the comfort of your own home August 21-23, 2020. Save the dates! More information will be available soon.

We hope you will join us for our 10th survivorship conference as we celebrate hope.

Keeping lung cancer research going

This is a critical time to fund lung cancer research. In 2020 alone, there have been 10 treatment approvals for lung cancer. This progress is exciting, but the momentum cannot stop here. Now more than ever, prioritizing funds for lung cancer research ensures a pipeline of the best and brightest young researchers to continue this progress.

Help LUNGevity keep research going! As labs around the country begin to reopen, we are hitting the ground running with our established, robust research funding portfolio, which includes our fourth year investing in a Stand Up To Cancer grant focused on lung cancer interception and early detection, research partnerships with oncogene-driven patient groups, and our longstanding Career Development Awards for outstanding young scientists.

Lung cancer news from ASCO

This year’s American Society of Clinical Oncology (ASCO) meeting, usually held in Chicago with over 40,000 oncology professionals in attendance, was a virtual event. Despite this, the meeting was full of exciting research presentations and important updates about lung cancer.

Dr. Upal Basu Roy, LUNGevity’s VP of Research, discusses some of the major lung cancer findings presented at this year’s ASCO conference as well as recent drug approvals and what it means for the lung cancer community in our ASCO Highlights blog post.

Dr. Basu Roy reminds us that lung cancer research continues, and so do lung cancer drug approvals. Be sure to check it out!

LUNGevity welcomes new board members

William “BJ” Jones, Chief Commercial Officer, Migraine and Common Disease at Biohaven Pharmaceuticals, and Robert Winn, MD, Director, Virginia Commonwealth University Massey Cancer Center Richmond, VA, have joined LUNGevity’s Board of Directors.

BJ’s extensive commercial leadership experience at pioneering companies in the healthcare industry will provide strategic insight and guidance to the Foundation in its work of changing outcomes for people with lung cancer. 

Dr. Winn brings years of experience in lung health and specifically lung cancer along with a passion for health equity and diversity that will help the Foundation grow strategically in ways that will have maximum impact on all who are affected by lung cancer.

We are honored to have them join our Board of Directors. Learn more about BJ Jones and Dr. Robert Winn in the press releases, and learn more about LUNGevity’s Board of Directors by visiting our website.

Thank you for joining us for Breathe Deep TOGETHER

Did you miss the event but still want to get involved? You can still make a difference. Watch the live stream from the event, walk the 5K, and donate today!